GLP-3 (Retatrutide)

Buy Retatrutide in Canada — Triple-Agonist Research Peptide

Retatrutide is a 39-amino-acid investigational peptide and the first triple agonist of the GLP-1, GIP, and glucagon receptors to enter advanced clinical research. Researchers looking to buy retatrutide in Canada for laboratory investigation will find it studied across metabolic, glycemic, and adiposity-related endpoints in animal models and published trial data.

Engineered with non-natural amino acid substitutions and a lipid moiety that extends plasma half-life, retatrutide engages three incretin and glucagon-family receptors simultaneously. Published preclinical and Phase 2 trial data describe coordinated effects on energy intake, hepatic substrate handling, and adipose mobilization that distinguish it from single-incretin compounds. The compound is currently under investigation in Eli Lilly's TRIUMPH clinical program.

Product Details

• Form: Lyophilized peptide
• Net per vial: 10 mg (filled to approximately 104% of label)
• Purity: ≥99% (HPLC-verified)
• Identity: MS-verified (per COA)
• Storage: 2–8 °C, protect from light
• Formula / M.W.: Available on batch-specific COA
• CAS: 2381089-83-2

What Makes Retatrutide a Unique Compound

Retatrutide is the only compound in advanced clinical investigation that simultaneously activates the GLP-1, GIP, and glucagon receptors. Earlier incretin peptides target one or two; the addition of glucagon-receptor agonism reintroduces a hepatic and energy-expenditure dimension that mono- and dual-agonists cannot address.

Developed at Eli Lilly and disclosed in 2022 under the code LY3437943, retatrutide carries Aib substitutions for DPP-4 resistance and a C20 fatty diacid for albumin binding and extended circulation. Phase 2 trial data published in 2023 in major peer-reviewed medical journals reported dose-dependent changes in body weight and HbA1c, making it a reference tool compound for researchers comparing the contributions of each receptor pathway.

Key Benefits

• Glycemic Regulation — Phase 2 trial data published in 2023 reported dose-dependent reductions in HbA1c in study populations with type 2 diabetes, supporting investigation into the contribution of triple-receptor activation to glucose handling.
• Adiposity & Body Composition — Animal and clinical trial datasets describe substantial reductions in fat mass over 24- and 48-week protocols, with investigators attributing the magnitude to combined incretin and glucagon-receptor effects on intake and expenditure.
• Hepatic Lipid Metabolism — Researchers studying NAFLD and MASH models have examined retatrutide's effect on hepatic triglyceride content, where glucagon-receptor agonism is hypothesized to drive intrahepatic lipid mobilization beyond what GLP-1 alone produces.
• Energy Expenditure — Preclinical work in rodent models has reported elevations in resting energy expenditure attributed to the glucagon receptor component, distinguishing retatrutide from GLP-1 monotherapy in mechanistic dissection studies.
• Cardiometabolic Markers — Secondary endpoints in published trials have included blood pressure, lipid panel, and inflammatory markers, giving researchers additional data points for modeling broader cardiometabolic effects of triple agonism.

Synergistic Peptides

Researchers working with retatrutide often investigate it alongside:

• Tesamorelin — GH-axis analog studied in visceral adiposity and lipid metabolism research; useful mechanistic contrast to incretin-driven fat mass effects.
• MOTS-c — Mitochondria-derived peptide investigated for insulin sensitivity and exercise-mimetic activity; complements retatrutide's receptor-level metabolic effects with a cellular-energetics angle.
• NAD+ — Mitochondrial cofactor studied alongside metabolic peptides in cardiometabolic and longevity research designs.

Frequently Asked Questions

How is retatrutide different from tirzepatide or semaglutide?

Semaglutide is a single GLP-1 receptor agonist. Tirzepatide is a dual GLP-1/GIP agonist. Retatrutide adds a third arm — glucagon receptor agonism — which preclinical and Phase 2 data suggest contributes additional hepatic lipid mobilization and energy expenditure effects not observed with mono- or dual-agonist compounds.

What is the evidence base for retatrutide?

Phase 2 trials in obesity and type 2 diabetes have been completed and published in major peer-reviewed medical journals, including data on body weight, glycemic markers, and tolerability. Phase 3 development is ongoing under Eli Lilly's TRIUMPH program. The preclinical literature spans metabolic, hepatic, and energy-expenditure endpoints in rodent and non-human primate models.

Is retatrutide naturally occurring?

No. Retatrutide is a synthetic 39-amino-acid peptide engineered with non-natural Aib substitutions for protease resistance and a C20 fatty diacid acylation for extended circulation. It does not exist in nature; its sequence is designed to engage GLP-1, GIP, and glucagon receptors simultaneously.

⚠️ For research use only. Not intended for human or veterinary use. Not a drug, food, or supplement.